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Background: Bupropion and varenicline can substantially improve the chances of smoking 
cessation in patients with COPD, but are unsubsidized and relatively costly. We examined 
overall use and socioeconomic patterns of use among patients with COPD.
Patients and methods: We identified 4,741 COPD patients reporting to be smokers at their first 
contact for COPD during 2008–2012 in the Danish register of COPD, which covers all pulmonary out-
patient clinics in Denmark. Patients were followed for 6 months in the National Prescription Registry. 
Logistic regression analyses were used to calculate the ORs with corresponding 95% CI of redeeming 
a prescription for any of the smoking cessation medications in strata of baseline characteristics.
Results: During 6 months from first consultation, only 5% redeemed a prescription for bupropion 
or varenicline. Younger age, female sex, higher education, and higher income were associated 
with an increased likelihood, while non-Danish ethnicity, living alone, and very severe COPD 
were associated with a lower likelihood of redeeming bupropion or varenicline.
Conclusion: Despite their proven effectiveness, bupropion and varenicline are sparingly used 
among COPD patients followed in the hospital outpatient setting with the lowest use among the 
socioeconomically disadvantaged. This highlights a missed opportunity for intervention.
Keywords: bupropion, varenicline, smoking intervention, lung disease
Plain language summary
Smoking cessation is crucial for slowing the progression of COPD. Yet, a large proportion of 
patients with COPD continue to smoke with the lowest quit rates observed among socioeconomi-
cally disadvantaged groups. Prescription medications bupropion and varenicline are effective 
but expensive smoking cessation aids. We did this study to determine if COPD patients take 
advantage of this therapeutic option in their efforts to quit smoking and whether some subgroups 
are more or less likely to do so. 
Using the Danish register for COPD and the National Prescription Registry, we fol-
lowed 4,741 smokers with COPD for filling a prescription for bupropion or varenicline 
during six months from first outpatient clinic contact and calculated the odds according to 
socio-demographic patient characteristics. 
We found that bupropion and varenicline are sparingly used among COPD patients followed 
in the hospital outpatient setting overall with the lowest use among the socioeconomically 
disadvantaged. This highlights a missed opportunity for intervention.
Background
Smoking cessation is the most effective strategy to reduce respiratory symptoms1,2 
and slow the progression of COPD.2–7 Despite these clear benefits, multiple studies 
show that many COPD patients continue to smoke.8–11 In Denmark, a national audit 
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indicated that more than 30% of all patients followed in 
Danish hospital-based pulmonary outpatient clinics are 
active smokers.12 Recently, we showed that the probability 
of quitting smoking among COPD outpatients is only 19% 
after 1 year and 45% after 5 years, respectively.13 Patients 
who continue to smoke despite symptomatic COPD may 
have higher nicotine dependence relative to smokers without 
COPD.14 Patients who do not succeed in quitting smoking 
are generally younger, have milder COPD, more often live 
alone, and have a lower income.13 This could be indicative 
of inadequate intervention for achieving tobacco abstinence 
related to socioeconomic inequalities.
Doctors at hospital-based pulmonary outpatient clinics 
are well-placed to support smokers in quitting by providing 
prescriptions for smoking cessation medications (SCMs). 
Both bupropion and varenicline have been shown in random-
ized controlled trials and in real-world observational studies 
to substantially improve the chances of long-term smoking 
cessation in the general population15 and in patients with 
COPD.16–18 However, these medications are expensive and 
unlike most drugs for chronic diseases, there is no general 
public reimbursement for them in most countries including 
Denmark, making these drugs out of reach for the financially 
less well-off patients. To our knowledge, no previous study 
has examined how widespread the use of these medications 
is among patients with COPD.
In this nationwide population-based study, we examine 
the use of SCMs among outpatients with COPD who smoke 
and who were eligible for smoking cessation intervention. 
We also investigated clinical, demographic and socioeco-
nomic predictors for the use of SCMs. Our hypothesis was 
that patients who are younger and have milder COPD are 
less likely to redeem a prescription for SCMs compared with 
their older, more severely ill, counterparts. Furthermore, we 
hypothesized that patients with lower disposable income 
and lower education are less likely to redeem a prescription 
for SCMs relative to their high-income and high-educated 
fellow smokers.
Patients and methods
study population
In Denmark, stable, mild and moderate COPD is mainly 
managed by general practitioners (GPs). Patients with more 
severe COPD, those with frequent exacerbations or rapidly 
progressing disease are referred to pulmonary outpatient 
specialist clinics based in public hospitals. From 2008, the 
nationwide Danish Register of COPD (DrCOPD) has con-
tinuously monitored these outpatients in all of Denmark. 
Details of the DrCOPD have been described previously.12,19 
Briefly, with the DrCOPD, all hospital-based outpatient 
clinics are committed to register and report a set of clinical 
variables including smoking status and pulmonary function 
(assessed as forced expiratory volume in 1 second [FEV
1
] 
% predicted) for each COPD patient who is followed at the 
clinic at least once a year. During 2008–2012, a total of 
23,741 individuals with a first-ever outpatient contact for 
COPD were enrolled of which 4,741 reported to be current 
smokers and thus eligible for this study.
Prescription medications for smoking 
cessation
Use of SCMs was identified searching the Danish Prescrip-
tion Registry (DPR) for filled prescriptions of bupropion 
(Anatomical Therapeutic Chemical [ATC] Classification 
code N06AX12) and varenicline (ATC code N07BA03) 
among smokers during 6 months from first outpatient visit 
in the DrCOPD. Patients who either died or migrated before 
the end of the observation period were excluded (N=796). 
The DPR holds complete information on all out-of-hospital 
dispensed prescriptions at pharmacies and nursing homes.20 
Previous use of SCMs was identified searching for prescrip-
tions filled in the year 2000, where bupropion was introduced 
to the Danish market and up to the date of first outpatient 
visit, and in 2006, where varenicline was introduced and 
first outpatient visit.
Clinical and sociodemographic variables
Statistics Denmark provided data on age (30–49, 50–69 
and $70 years), sex (male and female) and cohabitation 
status (any other person who is not a dependent categorized 
as cohabiting and not cohabiting). Severity of airflow limita-
tion was recorded as FEV
1
%pred from DrCOPD according 
to GOLD 1–4 staging.21 Educational attainment was catego-
rized as primary/lower secondary (elementary school), upper 
secondary (high school) and tertiary (university). Family 
equalized disposable income (calculated as total income 
including estimated rental value before deduction of interest 
expenses minus total tax deductible interest expenses, includ-
ing interest expenses in business minus total taxes including 
labor market contributions and special pension contributions 
minus paid tax deductible maintenance allowance minus 
reimbursed cash benefits taking into account the number and 
age of persons in the household) the year before baseline was 
divided into tertiles (low, medium and high).
statistical analyses
As prescription data were only available until the end of 
2012, 576 participants with a first outpatient visit later than 
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June 30, 2012, were excluded due to follow-up shorter than 
the required 6 months. The 220 patients who died before 
the 6 months mark were included for analyses. Among 
the remaining 4,165 smokers with COPD, we calculated 
the proportion who claimed a prescription for bupropion 
and/or varenicline during the 6 months following first 
outpatient contact for the population as a whole, and 
in strata of baseline characteristics and previous use of 
SCMs. Multiple logistic regression analyses were used to 
calculate the OR with corresponding 95% CI of redeeming 
a prescription for any SCM. The identification of poten-
tial confounders was guided by previous knowledge and 
the methods of directed acyclic graphs.22 Analyses were 
performed using STATA-14 (StataCorp, College Station, 
TX, USA).
ethical approval
The study was approved by the Danish Data Protection 
Agency (record 2012-41-0438), the Danish National Indi-
cator Project, Danish Regions and the Danish Ministry of 
Health.
Results
Among the 4,165 smokers with COPD, the vast majority 
was above 50 years of age (91%) and of Danish origin 
(96%). Sex, cohabitation status and disposable income were 
equally distributed and the majority of patients had COPD 
severity corresponding to GOLD 2 and 3 (46% and 35%, 
respectively). As expected for a relatively older population, 
elementary school was the highest attained education for 
56% while 37% had finished high school.
During 6 months from first outpatient visit, only 5% 
redeemed any prescription for SCM, with 1% redeeming 
bupropion and 4% redeeming varenicline. We did not observe 
any temporal trends in the use of SCMs during the study 
period (results not shown).
Table 1 shows proportions as well as crude and con-
founder adjusted ORs with corresponding 95% CI of 
redeeming any SCM within 6 months from first outpatient 
visit according to baseline clinical and sociodemographic 
characteristics and previous use of SCMs.
Confounder adjusted analyses showed that patients aged 
30–49 (OR 1.90, 95% CI 1.10–3.30) and 50–69 (OR 2.21, 
95% CI 1.58–3.12) years had an ~2-fold increased likelihood 
of redeeming an SCM compared with patients older than 
70 years of age. The association persisted after excluding 
patients, who died within the follow-up period (data not 
shown). The observed age differences in the use of SCMs 
could neither be explained by education and income, which 
are generally higher among the younger age groups, nor by 
a higher degree of cohabiting and milder disease.
In age- and ethnicity-adjusted analyses, females were 
more likely to redeem an SCM prescription (OR 1.40, 95% CI 
1.10–3.30) compared with males. The association persisted 
after additional inclusion of potential mediating factors as 
education, income, cohabitation and COPD severity.
Confounder adjusted analyses suggested that smokers of 
non-Danish origin have substantially lower odds of redeem-
ing an SCM (OR 0.35, 95% CI 0.11–1.12) compared with 
native Danes. Further adjustment for education and income, 
which is generally lower among non-Danes, attenuated this 
association slightly.
Smokers with the highest education were more than twice 
as likely to redeem an SCM prescription (OR 2.03, 95% CI 
1.28–3.22) relative to patients with the lowest education 
when adjusting for confounders. A generally higher income, 
higher likelihood of cohabiting and lower COPD severity 
among patients with a university degree explained about a 
one-fourth of the increased likelihood. 
A gradient in the use of SCMs was observed for income, 
with patients belonging to the middle and highest income 
groups having ORs of redeeming an SCM of 1.59 (95% 
CI 1.05–2.41) and 1.91 (95% CI 1.26–2.90), respectively, 
when compared with patients in the lowest income group. 
A generally higher proportion cohabiting and milder 
COPD severity explained some, but not all of the increased 
likelihood.
Patients who lived alone were less likely to redeem an 
SCM prescription (OR 0.76, 95% CI 0.56–1.04) compared 
with patients who cohabited. Differences in COPD severity 
could not explain the observed difference.
Mild COPD corresponding to GOLD 1 was associated 
with lower odds of redeeming an SCM prescription (OR 
0.39, 95% CI 0.18–0.86) when compared with severe COPD 
(GOLD 3), which was the most common severity level in the 
population. Although not materially different from patients 
in GOLD group 3, patients with GOLD 4 were less likely 
to redeem an SCM; this association was not explained by 
higher 6-month mortality in the more severe COPD group 
(results not shown).
Discussion
Despite the well-documented effectiveness of bupropion and 
varenicline for smoking cessation among persistent smokers 
with COPD,16–18 studies on the use of these medications 
among patients initiating specialized outpatient care are 
virtually nonexisting. This exact time in the patient’s history 
of disease is a relevant point of intervention as patients who 
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continue to smoke despite the progression of their disease 
likely have special needs in order to quit.
Our study shows that the use of prescription medica-
tions for smoking cessation among persistent smokers with 
COPD is low, with only 5% redeeming a prescription within 
6 months of first outpatient visit. The study further shows 
substantial clinical and sociodemographic inequalities in 
the use of SCMs with a higher chance of redeeming SCM 
in younger individuals, women, those with Danish origin, 
highest income and education, those living with a partner 
and those with either mildest or most severe COPD.
Smoking cessation is beneficial in COPD patients of all 
ages, and to our knowledge, SCMs have not been shown 
less efficacious in older compared with younger smokers. 
It is possible that conscious or subconscious ageism by 
physicians may explain the lower SMC prescription rate 
among older patients. It is well-known that older people with 
chronic conditions tend to have a lower use of statins and 
a lower use of newer antidiabetic drugs23 and receive less 
aggressive medical cancer treatments than younger patients.24 
Alternatively, patient preferences or higher price sensitivity 
in regard to smoking cessation aids among older individuals 
might explain the lower use of SMCs.
This study showed a higher likelihood in female than in 
male smokers to initiate SCM when starting in COPD outpa-
tient care. In a recent study by McKee et al, women reported 
greater perceived benefits of smoking cessation compared 
with men, and that perceived benefits were associated with a 
motivation to quit.25 Simultaneously, women reported lower 
self-efficacy in their ability to resist smoking in situations 
involving negative affect,26 and have been found to more 
accurately remember past withdrawal, while men tend to 
minimize symptoms.27 On the basis of these studies, one 
could hypothesize that women are more motivated to quit, 
Table 1 Proportion and corresponding Or with 95% CI of claiming any prescription for either bupropion or varenicline within 
6 months from first outpatient visit for COPD according to baseline characteristics
Sociodemographic 
characteristics
Any SCM Crude Confounder 
adjusted
+Mediator 
adjusted
n/N (%) OR (95% CI) OR (95% CI)
age (years)*
.70 45/1,536 (3) 1 (ref) 1 (ref) 1 (ref)
50–69 139/2,272 (6) 2.16 (1.53–3.04) 2.21 (1.58–3.12) 1.85 (1.28–2.67)
30–49 19/357 (5) 1.86 (1.08–3.23) 1.90 (1.10–3.30) 2.01 (1.13–3.57)
sex‡
Male 83/2,019 (4) 1 (ref) 1 (ref) 1 (ref)
Female 119/2,143 (6) 1.37 (1.03–1.83) 1.40 (1.05–1.86) 1.39 (1.03–1.89)
ethnicity§
Danish origin 199/4,008 (5) 1 (ref) 1 (ref) 1 (ref)
Other origin 3/154 (2) 0.39 (0.12–1.20) 0.35 (0.11–1.12) 0.44 (1.14–1.43)
education║
elementary school 100/2,257 (4) 1 (ref) 1 (ref) 1 (ref)
high school 72/1,468 (5) 1.11 (0.82–1.52) 1.08 (0.79–1.48) 1.01 (0.72–1.41)
University 25/290 (9) 2.04 (1.29–3.21) 2.03 (1.28–3.22) 1.79 (1.09–2.96)
Income¶
low 38/1,339 (3) 1 (ref) 1 (ref) 1 (ref)
Medium 69/1,349 (5) 1.85 (1.23–2.76) 1.59 (1.05–2.41) 1.49 (0.98–2.28)
high 89/1,326 (7) 2.46 (1.67–3.63) 1.91 (1.26–2.90) 1.68 (1.09–2.60)
Cohabitation#
Cohabitating 112/2,022 (6) 1 (ref) 1 (ref) 1 (ref)
living alone 90/2,137 (4) 0.75 (0.56–1.00) 0.76 (0.56–1.04) 0.73 (0.53–1.00)
gOlD 1–4**
1 7/273 (3) 0.43 (0.20–0.94) 0.39 (0.18–0.86)
2 87/1,844 (5) 0.81 (0.60–1.11) 0.77 (0.56–1.07)
3 82/1,426 (6) 1 (ref) 1 (ref)
4 22/497 (4) 0.76 (0.47–1.23) 0.84 (0.51–1.37) n/a
Previous sCM**
no 3,334/4,165 (80) 1 (ref) 1 (ref)
Yes 831/4,165 (20) 3.54 (2.65–4.72) 3.21 (2.37–4.35)
Notes: adjustments: *confounders: sex and ethnicity. Mediators: +education, income, cohabitation, and COPD severity; ‡confounders: age and ethnicity. Mediators: 
+education, income, cohabitation, and COPD severity; §confounders: sex and age. Mediators: +education, income, cohabitation, and COPD severity; ║confounders: age, 
sex and ethnicity. Mediators: +income, cohabitation, and COPD severity; ¶confounders: age, sex, ethnicity and education. Mediators: +cohabitation and COPD severity; 
#confounders: confounders: age, sex, ethnicity, education, and income. Mediators: +COPD severity; **confounders: age, sex, ethnicity, education, income, and cohabitation. 
no mediators.
Abbreviations: Or, odds ratio; gOlD, The global Initiative for Chronic Obstructive lung Disease; sCM, smoking cessation medication; ref, reference; n/a, not applicable.
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but to a lesser extent rely on their own willpower in smoking 
cessation attempts, consequently being more proactive and/or 
open to trying SCMs. An alternative explanation may be that 
men to a larger extent prefer other therapeutic options such 
as nicotine replacement therapy.
Smokers of non-Danish origin were less likely than native 
Danes to redeem an SCM. In a recent study, we found that 
patients of non-Danish origin were considerably less likely 
to use any inhaled maintenance medication compared with 
ethnic Danes.28 In both the previous and the current studies, 
the association between ethnicity and medicine use was 
adjusted for a range of potential explanatory factors includ-
ing education and income. Although these are generally 
lower among non-Danish patients, this did not explain the 
association. An explanation for the lower SCM initiation may 
be cultural and language barriers as well as different health 
belief models, which could affect the patient’s understanding 
and willingness in taking SCMs.
In this study addressing socioeconomic difference in 
SCM use among COPD patients who smoke, having a higher 
education and higher income nearly doubled the likelihood 
of redeeming an SCM. Given the relatively high cost of these 
medications, this socioeconomic skew comes as no surprise. 
In Denmark in 2016, the recommended 12-week treatment 
with varenicline sold as Champix® (Pfizer, New York, NY, 
USA) is 316 Euros, while the shortest recommended treat-
ment course of 7 weeks with bupropion sold as Zyban® (GSK 
Pharma, Brentford, UK) is 124 Euros. In contrast to the 
majority of medications for chronic conditions in Denmark, 
SCMs are not subsidized, which could explain why the 
use is so much higher among the more well-off patients, 
which, in turn, could help to explain the higher quit rates 
observed among more affluent smokers with COPD.13 A 
2012 Cochrane systematic review concluded that financial 
interventions directed at smokers when compared with no 
financial interventions increase the proportion of smokers 
who attempt to quit, use smoking cessation treatments and 
succeed in quitting.29 Such a strategy could be particularly 
beneficial for low SES patients who to a larger extent report 
financial motivations for wanting to quit30 as they would 
experience a more immediate financial upside by quitting 
instead of merely replacing tobacco expenses with expenses 
for SMCs in the first critical phase of quitting.
The present study also showed that living alone is associ-
ated with lower SCM use and that this was independent of age, 
sex, ethnicity, education and income. We speculate that moti-
vation from a partner may play a role in explaining the higher 
likelihood of SCM use among cohabiting COPD patients.
We observed an association between GOLD stage and use 
of SMC. In a previous study using data from the DrCOPD, 
we found an association between lower COPD severity and 
chance of quitting13 and another study observed activity 
limitation due to pulmonary symptoms to be associated 
with smoking cessation.31 Hence, patients who have milder 
COPD may feel less motivated to quit or may prefer and 
agree with the managing physician to try quitting unassisted, 
which could explain the lower use of SCM in this group. 
Furthermore, we wonder if the seemingly lower chance of 
redeeming an SMC among the very severely ill patients could 
be due to the physician “giving up” on these particularly 
persistent smokers. This notion is supported by a recent 
multinational qualitative study, where Eerd et al found that 
doctors’ frustrations and negative attitudes toward COPD 
patients who continued to smoke contributed to poor cessa-
tion management and treatment inequalities in some cases. 
Many doctors also cited a lack of experience with smoking 
cessation techniques alongside time and money issues as to 
effective treatment.32
Finally, the study showed that the previous use of SCM 
was a strong predictor for repeated use. This could be reflec-
tive of a higher motivation for stopping and implicitly COPD 
patients more proactive and receptive to using cessation 
aids. However, it could also reflect a degree of continuous 
use instead of the recommended treatment course of up to 
12 weeks.
strengths and limitations
Our study has several major strengths. The prospective design 
ensured the ability to assess the redemption of prescriptions 
in the months following the initiation of management in 
outpatient clinics, a critical moment to intensify efforts for 
the patient to achieve abstinence. Independently collected 
data on socioeconomic factors and COPD severity from high 
validity national registers were available on most subjects. 
The use of the extensive Danish prescription registry to 
account for patient use of SCMs was another major strength 
as it completely removes the biases due to recall. However, 
we are likely to have under-ascertained the prescription prac-
tices of the physicians, as pharmacy records only account for 
claimed medications. Therefore, we cannot be sure whether 
part of the non-use of SCM is due to the patient not claiming 
a prescription issued by the managing physicians. Indeed, 
medication nonadherence – not taking pharmacologic treat-
ments according to agreed recommendations from a health 
care provider – is common in patients with COPD.33,34 If less 
affluent COPD patients are less likely to redeem an issued 
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SCM prescription than their better-off counterparts, we may 
have accentuated the difference in prescription practices with 
the data available. Furthermore, the prescription registry 
does not hold information on nicotine replacement therapy, 
which is primarily sold over-the-counter and is cheaper than 
both varenicline and bupropion. Thus, patients who did not 
claim an SCM may be in treatment with nicotine replace-
ment therapy, be participating in other smoking cessation 
interventions or have taken up electronic cigarettes as a 
means of risk reduction, although the latter were not widely 
used in Denmark during the study period. Regardless the 
possible use of alternative interventions for smoking cessa-
tion, our findings show a worryingly low use of documented 
effective SCMs among smokers with COPD followed in the 
outpatient setting.
Conclusion
Bupropion and varenicline for smoking cessation are being 
sparingly used in general and with significantly lower usage 
among socioeconomically disadvantaged patients and 
patients with less severe disease. These inequalities may 
contribute to the observed low quit rates in these patient 
groups. The vast importance of smoking cessation in slowing 
the progression of COPD and improving overall prognosis of 
this high-risk population calls for continuous efforts to ensure 
equal and timely access to effective cessation medications. It 
could be argued that individuals with COPD would benefit 
from reimbursed SCMs on similar principles as for other 
maintenance medications for COPD.
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